AI-Mind presents results at Alzheimer Europe conference in Geneva
The 34th Alzheimer Europe Conference (#34AEC) took place from 8-10 October in Geneva (Switzerland) bringing together over 950 delegates from 42 European countries under the theme “New horizons – Innovating for dementia.”. On the agenda were over 400 presenters sharing their research, knowledge and experience in a collaborative atmosphere. The AI-Mind project made a significant impact during the event by unveiling its latest research findings. This milestone marked a key moment for the project, which focused on developing Artificial Intelligence digital tools for screening brain connectivity and dementia risk estimation. These tools aim to support healthcare professionals in their diagnosis and enable them to predict which people with Mild Cognitive Impairment (MCI) are likely to develop dementia.
A major highlight was the participation of AI-Mind’s project coordinator, Dr. Ira Haraldsen, taking the stage as a keynote speaker in the final plenary session on brain health and prevention. She highlighted the innovative potential of artificial intelligence in dementia research, particularly in risk prediction and early diagnosis, signalling promising advancements for the future.
Throughout the conference, AI-Mind Consortium members presented groundbreaking AI-Mind research and findings, including:
- “Exploring APOE Genotypes and Plasma p-Tau Biomarkers in European MCI Populations: Insights from the AI-MIND Project” delivered by Vebjørn Andersson. This presentation offered new insights into how certain biomarkers, combined with genetic information, can enhance the early detection of cognitive decline.
- “The innovative AI-Mind data collecting framework – a user-centric way of diagnosing mild cognitive impairment” presented by Ira Haraldsen. This talk focused on the project’s cutting-edge data collection approach, designed to improve MCI diagnosis.
- “Associations Between Plasma p-tau217 and Neuropsychological Test Performance in Mild Cognitive Impairment: Baseline Data of the AI-Mind Study” by Ana Perez. The presentation explored the correlation between specific biomarkers and cognitive performance, highlighting the potential of blood-based biomarkers for diagnosis.
- “eBRAIN-health and its federated nodes – synergies and virtual opportunities for personalized neurological medicine” by Ira Haraldsen. This talk explored the example of the AI-Mind project, integrated with the eBRAIN-Health initiative that aims to enhance the use of distributed medical data through federated learning.
As the AI-Mind project continues to advance the field of artificial intelligence in dementia prevention, the consortium looks forward to reconvening in Madrid at the end of October for its Project General Assembly Meeting. Additionally, members will continue to disseminate their findings at conferences such as the upcoming 17th Clinical Trials on Alzheimer’s Disease (CTAD) to be held on October 29 – November 1, 2024.